Healthcare Clinical Trial Simulation
This synthetic clinical trial dataset provides detailed, patient-level records for multi-arm studies, including demographics, treatment assignments, protocol compliance, outcomes, and adverse event tracking. It is ideal for modeling trial efficacy, safety profiles, and protocol adherence in simulated or methodological research. The flat structure ensures compatibility with statistical and machine learning tools for rapid analysis and simulation.
Sample rows
preview · 8 of 200 rows · all 21 columns| patient_idstring | primary_outcomestring | protocol_compliancefloat | dropoutboolean | ethnicitystring | trial_idstring | arm_idstring | arm_descriptionstring | enrollment_datedate | ageinteger | sexstring | baseline_conditionstring | comorbiditiesstring | secondary_outcomestring | adverse_event_occurredboolean | adverse_event_typestring | adverse_event_severitystring | adverse_event_onset_datedate | adverse_event_outcomestring | dropout_reasonstring | completion_datedate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P000001 | improved | 97 | false | Caucasian | T1 | A-T1-01 | Placebo | 2020-03-15 | 5 | male | Congenital Heart Disease | blank | surgical outcome good | false | blank | blank | blank | blank | blank | 2021-03-16 |
| P000002 | responder | 92.6 | false | Asian | T1 | A-T1-02 | Drug A 50mg | 2020-03-17 | 42 | female | Type 2 Diabetes | Hypertension,Obesity | HbA1c improved | false | blank | blank | blank | blank | blank | 2021-03-20 |
| P000003 | non-responder | 89.2 | false | African American | T1 | A-T1-03 | Drug B 10mg | 2020-03-20 | 55 | female | Hypertension | Hyperlipidemia | BP unchanged | true | Dizziness | mild | 2020-05-10 | resolved | blank | 2021-03-20 |
| P000004 | unchanged | 94.7 | false | Hispanic | T1 | A-T1-01 | Placebo | 2020-03-22 | 60 | male | Type 2 Diabetes | Obesity | HbA1c unchanged | false | blank | blank | blank | blank | blank | 2021-03-22 |
| P000005 | unchanged | 78.5 | false | Caucasian | T2 | A-T2-01 | Device X | 2021-09-18 | 77 | female | Alzheimer's Disease | Hypertension,Osteoporosis | minor cognitive improvement | true | Headache | moderate | 2021-11-01 | resolved | blank | 2022-09-18 |
| P000006 | unchanged | 88 | false | Native American | T2 | A-T2-02 | Placebo | 2021-09-20 | 80 | female | Chronic Pain | blank | joint pain unchanged | false | blank | blank | blank | blank | blank | 2022-09-22 |
| P000007 | improved | 81.9 | false | Other | T2 | A-T2-03 | Device X | 2021-09-22 | 75 | male | Rheumatoid Arthritis | Osteoporosis | joint pain reduced | true | Nausea | moderate | 2021-11-30 | resolved | blank | 2022-09-23 |
| P000008 | unchanged | 68.2 | true | Caucasian | T2 | A-T2-02 | Placebo | 2021-09-24 | 72 | female | Alzheimer's Disease | Arthritis | minor cognitive improvement | false | blank | blank | blank | blank | Lost to follow-up | 2022-01-30 |
| P000009 | improved | 95.5 | false | Hispanic | T3 | A-T3-01 | Surgery A | 2022-04-10 | 4 | female | Rare Genetic Disorder | blank | good surgical outcome | true | Surgical Complication | severe | 2022-04-18 | resolved | blank | 2023-04-10 |
| P000010 | responder | 98.8 | false | Other | T3 | A-T3-02 | Surgery B | 2022-04-15 | 3 | male | Congenital Heart Disease | blank | surgical outcome good | false | blank | blank | blank | blank | blank | 2023-04-15 |
| P000011 | improved | 92.1 | false | Asian | T3 | A-T3-03 | Placebo | 2022-04-17 | 2 | female | Congenital Heart Disease | blank | blank | false | blank | blank | blank | blank | blank | 2023-04-17 |
| P000012 | responder | 80.2 | false | Middle Eastern | T4 | A-T4-01 | Drug X 200mg | 2021-11-10 | 38 | female | Melanoma | Asthma | tumor size reduced | true | Neutropenia | life-threatening | 2021-11-17 | resolved | blank | 2022-11-10 |
| P000013 | non-responder | 88.7 | false | Pacific Islander | T4 | A-T4-02 | Placebo | 2021-11-12 | 41 | male | Melanoma | blank | tumor size unchanged | false | blank | blank | blank | blank | blank | 2022-11-12 |
| P000014 | improved | 96.4 | false | Black | T4 | A-T4-01 | Drug X 200mg | 2021-11-14 | 35 | female | COVID-19 | blank | hospitalization avoided | true | Fever | mild | 2021-11-20 | resolved | blank | 2022-11-15 |
| P000015 | responder | 87.4 | false | blank | T5 | A-T5-01 | Drug Q 400mg | 2023-01-02 | 50 | male | Hypertension | Hyperlipidemia,Obesity | BP reduced | false | blank | blank | blank | blank | blank | 2024-01-02 |
| P000016 | non-responder | 94.2 | false | Caucasian | T5 | A-T5-02 | Placebo | 2023-01-03 | 58 | male | Hypertension | blank | BP unchanged | false | blank | blank | blank | blank | blank | 2024-01-04 |
| P000017 | improved | 74.9 | false | African American | T5 | A-T5-01 | Drug Q 400mg | 2023-01-05 | 45 | female | Type 2 Diabetes | CKD | HbA1c improved | true | Hypoglycemia | moderate | 2023-02-01 | resolved | blank | 2024-01-05 |
| P000018 | responder | 96 | false | Hispanic | T6 | A-T6-01 | Drug S 20mg | 2023-02-10 | 16 | other | Epilepsy | Obesity | seizure frequency decreased | false | blank | blank | blank | blank | blank | 2024-02-10 |
| P000019 | improved | 99.1 | false | Caucasian | T6 | A-T6-02 | Surgery | 2023-02-12 | 25 | female | Epilepsy | blank | surgical outcome good | true | Infection | moderate | 2023-02-22 | resolved | blank | 2024-02-12 |
| P000020 | responder | 97.6 | false | Other | T6 | A-T6-01 | Drug S 20mg | 2023-02-15 | 40 | male | Congenital Heart Disease | blank | blank | false | blank | blank | blank | blank | blank | 2024-02-15 |
What the 200 rows show
from the 200-row sampleUnchanged (primary outcome) stands out: 17 of its 58 rows have dropout = true, against 5 of 142 for the rest.
- 11%dropout = true
- 91.2median protocol_
compliance - 2adverse event outcomes
- 4sexes
- 4adverse event severities
- 11baseline conditions
Median 91.2, from 59.0 to 100.0.
- string 14
- integer 1
- float 1
- date 3
- boolean 2
Columns
21 columns in four groups| column | type | description | example |
|---|---|---|---|
| Text 14 columns | |||
patient_id | string | Unique identifier for each patient enrolled in the clinical trial.unique | P000001 |
trial_id | string | Unique identifier for the clinical trial. | T1 |
arm_id | string | Identifier for the treatment arm to which the patient is assigned. | A-T1-01 |
arm_description | string | Description of the treatment arm (e.g., placebo, drug A, drug B). | Placebo |
sex | string | Sex of the patient.male · female · other · unknown | male |
ethnicity | string | Ethnicity of the patient.9 ethnicities · optional | Caucasian |
baseline_condition | string | Primary medical condition or diagnosis at baseline.11 conditions | Congenital Heart Disease |
comorbidities | string | Comma-separated list of comorbid conditions at baseline.optional | Hypertension,Obesity |
primary_outcome | string | Primary outcome result for the patient (e.g., responder, non-responder, improved, unchanged).4 outcomes | improved |
secondary_outcome | string | Secondary outcome result for the patient, if applicable.optional | surgical outcome good |
adverse_event_type | string | Type of the most serious adverse event experienced (if any).optional | Dizziness |
adverse_event_severity | string | Severity of the most serious adverse event (e.g., mild, moderate, severe, life-threatening).mild · moderate · severe · life-threatening · none · optional | mild |
adverse_event_outcome | string | Outcome of the most serious adverse event (e.g., resolved, ongoing, fatal).2 outcomes · optional | resolved |
dropout_reason | string | Reason for dropout if applicable (e.g., adverse event, lost to follow-up, withdrawal of consent).9 reasons · optional | Lost to follow-up |
| Numbers 2 columns | |||
age | integer | Age of the patient at the time of enrollment.0 to 120 | 5 |
protocol_compliance | float | Percentage of protocol compliance for the patient (0-100).0 to 100 | 97 |
| Dates and times 3 columns | |||
enrollment_date | date | Date when the patient was enrolled in the trial. | 2020-03-15 |
adverse_event_onset_date | date | Date when the most serious adverse event began.optional | 2020-05-10 |
completion_date | date | Date when the patient completed or exited the trial.optional | 2021-03-16 |
| True or false 2 columns | |||
adverse_event_occurred | boolean | Indicates if the patient experienced any adverse event during the trial. | false |
dropout | boolean | Indicates if the patient dropped out of the trial. | false |
Use it for
A healthcare dashboard
The dropout rate, protocol_
compliance by primary_ outcome and a breakdown of ethnicity. Excel, Power BI or Tableau. Why do 22 of 200 rows have dropout = true?
A root-cause class exercise
Hand out the rows and one question. The answer is in the data, not in the brief.
- Patients200P00000197improvedP00000868.2unchangedP00002273unchanged
A software demo
Believable patients with trial_
id, arm_ id and arm_ description to fill a screen in front of a buyer.
blueprint · healthcare-clinical-trial-simulation
Behind this dataset
Same schema. As many rows as you need.
These 200 rows came out of a blueprint — 21 columns with generation rules behind each one. Open it in Data Factory to retune a column, add your own, wire in foreign keys, and run it at the size you actually need.
- Patients assigned to active or control arms
- Track dosages, visit dates, and outcome scores
- Adverse events flagged per patient
- Inclusion/exclusion criteria applied
- Multiple trial sites simulated
1 credit per row. Preview 20 rows free. Buy rows for the full run.
- Exports
- CSV, JSON, JSONL, Parquet, SQL, Excel, TSV, XML
- Licence
- yours to use, including commercially
- API slug
- healthcare-clinical-trial-simulation